Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 8INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Cervical Intraepithelial Neoplasia Grade 2/3 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 297Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Cytological Techniques × Clear all
NCT03366493 2017-12-08

The Study of Folate Receptor-Mediated Staining Solution (FRDâ„¢) In Cervical Lesion Detection

GY Highland Biotech LLC

Phase 3 Unknown
200 enrolled
Gynecologic

Cervical Intraepithelial Neoplasia Grade 2/3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡